CTA_IIT_CRUSH PAD: Real-world Outcomes Following Use of the Shockwave Intravascular Lithotripsy (IVL) Technology in Calcified Common Femoral Lesions

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Observational
SUMMARY

The primary goal of the study is to obtain effect size data on the use of Shockwave Intravascular Lithotripsy (IVL) technology in calcified common femoral lesions in patients with peripheral artery disease for a series of endpoints, including target lesion revascularization and health status, to enable future planning of comparative effectiveness research.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Subjects presenting with claudication or CLI by Rutherford Clinical Category 2, 3, 4, 5, or 6 of the target limbs

• Subject is a suitable candidate for angiography and endovascular intervention per the latest clinical guidelines

• Patient is scheduled to undergo treatment with Shockwave Intravascular Lithotripsy (IVL) technology followed by standard of care treatment with DCB, BMS, DES at the physician's discretion.

⁃ Angiographic Inclusion Criteria

• Target lesion that is located in a native, de novo common femoral artery

• Target lesion reference vessel diameter is between 4.0mm and 7.0mm by visual estimate.

• Target lesion is ≥70% stenosis by investigator via visual estimate.

• Target lesion length is ≤50mm for lesions 70-99% stenosed. Target lesion can be all or part of the 50mm treated zone.

• Chronic total occlusion, lesion length is ≤50mm of the total ≤50 mm target lesion.

• Calcification is at least moderate defined as presence of fluoroscopic evidence of calcification: 1) on parallel sides of the vessel and 2) extending \> 50% the length of the lesion if lesion is ≥50mm in length; or extending for minimum of 20mm if lesion is \<50mm in length.

Locations
United States
Connecticut
Yale New Haven Health
RECRUITING
New Haven
Contact Information
Primary
Kim Smolderen, PhD
kim.smolderen@yale.edu
203-737-7673
Time Frame
Start Date: 2021-12-01
Estimated Completion Date: 2027-06-01
Participants
Target number of participants: 50
Treatments
Shockwave Intravascular Lithotripsy (IVL)
Patients with calcified common-femoral artery disease, who are eligible to receive IVL per the FDA indications.
Sponsors
Collaborators: Brown University, Shockwave Medical, Inc.
Leads: Yale University

This content was sourced from clinicaltrials.gov